Table 2.

Individual clinical and functional data of participants with Duchenne muscular dystrophy including age, Motor Function Measure (MFM), body mass index (BMI), and use of drugs and orthotic devices.

Individual Clinical Features of DG Participants
Subject	Age (years)	MFM D1 (%)	MFM D2 (%)	MFM D3 (%)	MFM Total (%)	BMI	Drugs	Orthotic devices
A1	6	26	94	90	66	24.7	Periciazine, Prednisone, D vitamin	Night Splint
A2	6	46	89	90	72	17.5	none	Night Splint
A3	6	41	94	95	73	17.6	Prednisone	Night Splint and Hinged AFO
B1	8	49	97	100	78	19	Deflazacort, D vitamin	Night Splint and Hinged AFO
B2	8	59	100	100	83	15.4	Prednisone, D vitamin, Levothyroxine sodium	none
C1	9	56	100	100	82	19.1	Deflazacort, D vitamin, Calcium	Night Splint
C2	9	51	94	100	78	22	Prednisone, D vitamin, Risperidone, Maprotiline	Night Splint
C3	9	36	100	90	72	21.5	Deflazacort, D vitamin	Hinged AFO
D1	10	33	97	95	71	30.9	Prednisone, D vitamin	Night Splint and Hinged AFO
E1	11	38	94	100	73	20.9	Prednisone, Imipramine	Hinged AFO and Leaf-spring